Study of a new drug for advanced colorectal cancer with a specific genetic feature
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug (DES-1357) for people with a specific type of advanced colorectal cancer that has not responded to previous treatments. The drug is designed to target tumors with a genetic mismatch repair deficiency, potentially helping to slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have colorectal cancer that has spread and cannot be removed with surgery.
- Your tumor has a specific genetic feature called dMMR or MSI-High, which makes it more responsive to certain therapies.
- You have already tried at least one standard treatment (like pembrolizumab, nivolumab, or certain chemotherapy) and it stopped working or caused bad side effects.
- You are generally able to take care of yourself (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- Your blood counts and organ function (kidney, liver, blood clotting) are within acceptable ranges for the trial.
- You are willing to provide a tumor sample (fresh or stored) and, if you are of childbearing potential, agree to use effective contraception during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This trial tests a new drug (VVD-133214) combined with an existing immunotherapy (pembrolizumab) for advanced colorectal cancer that is mismatch repair deficient. It aims to see if the combination works better than pembrolizumab alone in shrinking or controlling the cancer.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.